Bolt Biotherapeutics, Inc.

NasdaqCM:BOLT Rapport sur les actions

Capitalisation boursière : US$8.8m

Bolt Biotherapeutics Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Willie Quinn

Directeur général

US$4.6m

Rémunération totale

Pourcentage du salaire du PDG10.17%
Durée du mandat du directeur général6yrs
Propriété du PDG0.1%
Durée moyenne d'occupation des postes de direction2yrs
Durée moyenne du mandat des membres du conseil d'administration3.9yrs

Mises à jour récentes de la gestion

Recent updates

Article d’analyse • Nov 30

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse • May 21

Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding

Bolt Biotherapeutics, Inc. ( NASDAQ:BOLT ) shareholders that were waiting for something to happen have been dealt a...
Article d’analyse • Mar 15

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Article d’analyse • May 13

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Article d’analyse • Dec 01

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 26

Bolt Biotherapeutics: A Promised Follow Up

Summary Today, we post a promised follow-up on early stage biotech concern Bolt Biotherapeutics. The company has suffered some setbacks over the past year, but the stock now trades for approximately one-third of the cash on its balance sheet. We update the investment thesis around Bolt Biotherapeutics in the paragraphs below. "Pride is always a better lever against the nobility than reason." - Patrick Rothfuss, The Wise Man's Fear In our first article on biotech name Bolt Biotherapeutics, Inc. (BOLT) back in September of last year, we concluded by saying the company had some "potentially intriguing technology" but it was not investment worthy at the time. We also promised we would check back in on this name to see how it was progressing. Today, we follow up on Bolt Biotherapeutics via the analysis below. Seeking Alpha Company Overview: Bolt Biotherapeutics is headquartered in California. The company is developing drug candidates using its Boltbody immune-stimulating antibody conjugate (ISAC) platform. This technology is being applied to create a new category of immunotherapies that generate a robust anti-tumor immune response by combining the precision of antibody targeting with the strength of the innate and adaptive immune systems. By activating and recruiting myeloid cells, Boltbody ISACs re-program the tumor microenvironment to invoke a new anti-tumor immune response. Company Website Myeloid cells are a group of immune cells that belong to the innate immune system. They consist of cell types known as monocytes, macrophages, dendritic cells, and granulocytes. These cells serve many essential roles in the body's immune system. When these cells are functioning properly, they can stimulate anti-tumor effects in the body. Including the activation of tumor-specific T cells to support durable anti-tumor immune responses and immunological memory. Immunosuppressive factors produced in the tumor microenvironment can impair the normal function of these cells. The stock currently trades around two bucks a share and sports an approximate market capitalization of $75 million. Recent Developments: The biggest news around the company since we last peaked in on it occurred early in December of last year. Bolt Biotherapeutics presented interim clinical data from its Phase 1/2 study of BDC-1001, its lead candidate, at the European Society for Medical Oncology Immuno-Oncology Congress. Early data showed 13 of the 40 tumor evaluable subjects with one durable partial response maintained through 52 weeks and multiple subjects achieving stable disease for >12 weeks. BDC - 1001 is currently in clinical development for the treatment of patients with HER2-expressing solid tumors, including subsets with HER2-low tumors. This data was good enough to support initiation of the combination therapy study with nivolumab, also known by its brand name Opdivo from Bristol-Myers Squibb (BMY). That said, the data did not meet investors' expectations as the market cut the stock in roughly half after interim results from the study became known. Weekly dosing with a study around a combination therapy with Opdivo has begun and should be noted. Company Website The company has one other compound in development currently. It is called BDC-3042. This candidate is a myeloid modulating agonist antibody that reawakens myeloid cells to attack tumor cells. Specifically, BDC-3042 will stimulate a novel target called Dectin-2. This is found in tumor-associated macrophages across a broad range of solid tumors. Stimulating Dectin-2 leads to tumor macrophage reprogramming and anti-cancer activity in the company's preclinical studies. BDC-3042 will target solid tumors with a high unmet lead. However, BDC-3042 is still in the pre-clinical phase and is currently in IND-enabling studies. Analyst Commentary & Balance Sheet: Analysts are mixed on Bolt's prospects at the moment. Morgan Stanley has a Hold rating on the stock. On August 11th, SVP Securities downgraded Bolt from Outperform to Market Perform and slashed its price target in half to $4 a share. SVB's analyst noted he sees "A long road to recovery" following the company's announced discontinuation of second Boltbody candidate BDC-2034, which was previously on track to enter the clinic in 2023. The discontinuation was prompted by non-human primate fatalities observed at mid- to high-dose levels in toxicology studies. That same day, both Stifel Nicolaus ($7 price target) and JonesTrading ($8 price target) maintained Buy ratings on Bolt Biotherapeutics. The company ended the second quarter with just over $220 million in cash and marketable securities on its balance sheet. Bolt burned through around $23 million during the quarter to fund all operations. The company has no long-term debt. Management has put in place measures to conserve cash as was summarized in its second quarter earnings press release.
Seeking Alpha • Aug 10

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

Bolt Biotherapeutics press release (NASDAQ:BOLT): Q2 GAAP EPS of -$0.61 beats by $0.08. Revenue of $1.39M beats by $0.89M.
Article d’analyse • Jul 27

We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Article d’analyse • Apr 12

We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Article d’analyse • Dec 03

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 18

Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies

Bolt has built out a next-generation immunotherapy platform to design biologics for cancers that are not accessible for the current standard-of-care. The company's lead asset, BDC-1001, is expected to complete phase 1 clinical trials later this year creating a window for an opportunistic investment. As the pipeline matures, Bolt will be able to build out their partnerships and transition their business toward a fully-integrated diversified model.
Article d’analyse • Aug 18

We're Hopeful That Bolt Biotherapeutics (NASDAQ:BOLT) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analyse de la rémunération des PDG

Comment la rémunération de Willie Quinn a-t-elle évolué par rapport aux bénéfices de Bolt Biotherapeutics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Mar 31 2026n/an/a

-US$30m

Dec 31 2025US$5mUS$464k

-US$33m

Sep 30 2025n/an/a

-US$43m

Jun 30 2025n/an/a

-US$51m

Mar 31 2025n/an/a

-US$63m

Dec 31 2024US$1mUS$454k

-US$63m

Sep 30 2024n/an/a

-US$65m

Jun 30 2024n/an/a

-US$66m

Mar 31 2024n/an/a

-US$63m

Dec 31 2023US$912kUS$442k

-US$69m

Sep 30 2023n/an/a

-US$71m

Jun 30 2023n/an/a

-US$77m

Mar 31 2023n/an/a

-US$81m

Dec 31 2022US$1mUS$423k

-US$88m

Sep 30 2022n/an/a

-US$95m

Jun 30 2022n/an/a

-US$97m

Mar 31 2022n/an/a

-US$98m

Dec 31 2021US$2mUS$395k

-US$99m

Sep 30 2021n/an/a

-US$102m

Jun 30 2021n/an/a

-US$89m

Mar 31 2021n/an/a

-US$77m

Dec 31 2020US$1mUS$239k

-US$61m

Rémunération vs marché: La rémunération totale de Willie ($USD 4.56M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 630.36K ).

Rémunération et revenus: La rémunération de Willie a augmenté alors que l'entreprise n'est pas rentable.

PDG

Willie Quinn (54 yo)

6yrs
Titularisation
US$4,558,368
Compensation

Mr. William P. Quinn, also known as Willie, is CEO, President & Director of Bolt Biotherapeutics, Inc. from May 15, 2024. He has been Chief Financial Officer at Bolt Biotherapeutics, Inc. since May 2020 an...

Équipe de direction

NomPositionTitularisationCompensationPropriété
William Quinn
CEO, CFO6yrsUS$4.56m0.12%
$ 10.6k
Grant Yonehiro
COO & Chief Business Officer2yrsUS$4.01m0.023%
$ 2.0k
Sarah Nemec
Senior VP of Finance & Principal Accounting Officer2yrspas de données0.049%
$ 4.4k
Michael Alonso
Senior Vice President of Research2yrspas de donnéespas de données
Justin Kenkel
Senior Principal Scientistno datapas de donnéespas de données
2.0yrs
Durée moyenne de l'emploi
54yo
Âge moyen

Gestion expérimentée: L'équipe de direction de BOLT est considérée comme expérimentée (ancienneté moyenne 2 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
William Quinn
CEO, CFO2yrsUS$4.56m0.12%
$ 10.6k
Kathleen LaPorte
Independent Director5.4yrsUS$600.25k0.0031%
$ 275.2
Nicole Onetto
Independent Director4.4yrsUS$310.70k0%
$ 0
Brian O'Callaghan
Independent Chairman4.5yrsUS$448.94k0%
$ 0
Jakob Dupont
Independent Director1.7yrsUS$191.84k0%
$ 0
Laura Berner
Independent Director3.4yrsUS$173.67k0%
$ 0
3.9yrs
Durée moyenne de l'emploi
58yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de BOLT sont considérés comme expérimentés (ancienneté moyenne 3.9 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/22 16:31
Cours de l'action en fin de journée2026/05/22 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Bolt Biotherapeutics, Inc. est couverte par 6 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Robert BurnsH.C. Wainwright & Co.
Boris PeakerJonesTrading Institutional Services, LLC
Chad MesserLake Street Capital Markets, LLC